Abstract
e11547 Background: Fulvestrant (F) is a pure antiestrogen drug approved for MBC of postmenopausal women with estrogen receptor positive disease. The CONFIRM trial has recently demonstrated that a double dose (500 mg/monthly) of F is superior to 250 mg/monthly dose as PFS in MBC. In elderly (age >65 years) patients (pts) HT is the preferred choice when disease is hormone sensitive. The aim of our study was to determine the comparative activity, toxicity and feasibility of two different schedule of F in elderly women with MBC. Methods: A retrospective study was carried out in elderly MBC pts treated between 2006-2013 with F after at least one HT. Pts received F 250 or 500 mg im every 28 days until progression. Median age was 70,5 years (66-84). ER e PR status was known in all pts: ER+/PR+ were 56 (94%), ER+/PR- 4 (6%). Histological type were: ductal 52 (86,6%), lobular 8 (13,4%). HER 2 was positive in 4 (6%) pts. All pts were metastatic: 20 (33%) with bone metastasis alone, 40 (66%) with visceral involvemen...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
